Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Clear cell renal cell carcinoma (ccRCC) is characterized by profound lipid metabolic dysregulation, yet the mechanisms linking peritumoral adipose tissue (PAT)-derived lipid metabolites to tumor aggressiveness remain poorly defined. Here, we identified lysophosphatidylethanolamine 18:1 ...
Learn the remission rate for kidney cancer, including RCC survival statistics, treatment outcomes, and factors that influence remission based on leading clinical evidence.
Study findings support revising current renal cell carcinoma staging to enhance treatment decision-making.
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups ...
... renal cell carcinoma ... renal cell carcinoma (RCC). The randomized, double-blind LITESPARK-022 trial (ClinicalTrials.gov Identifier ...
Real-world data show ipilimumab + nivolumab provides meaningful survival benefits in advanced Renal Cell Carcinoma, with outcomes shaped by risk, histology, and toxicity.
Clear cell renal cell carcinoma (ccRCC) is a common and aggressive kidney cancer with poor prognosis due to its frequent late-stage diagnosis and immunosuppressive tumor microenvironment (TME). While ccRCC is responsive to immunotherapies, treatment resistance remains a major challenge, ...
Petryshak et al developed and validated BMVision, an artificial intelligence tool designed to assist radiologists in diagnosing kidney cancer from CT scans. In a reader study with six radiologists, the tool reduces reporting time by 32%, improves detection of benign lesions, and increases ...
Purpose Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare and aggressive RCC subtype defined in the 2022 WHO classification. This study aimed to describe its imaging and clinicopathological features. Methods A retrospective analysis was conducted on 11 patients (12 ...
... 2 KEYMAKER-U03 trial tested novel pembrolizumab-based triplet regimens for first-line treatment of advanced clear cell renal cell carcinoma (ccRCC).
No results found.
Articles from Kidney Cancer UK
Kidney Cancer UK Paper Published in BJU International
A decade-long insight into patient views on kidney cancer care delivery
A paper on our Kidney Cancer UK 10-Year ...
First NKCA annual report recommends reduction in unwarranted variation
The first annual State of the Nation Report from the National Kidney Cancer Audit (NKCA) highlights unwarranted ...
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
"Patients with advanced renal cancer often have a long and difficult ... kidney cancer," added Darren R. Feldman, MD, Medical Oncologist ...
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC
Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.
Belzutifan Improves PFS in ccRCC Subgroups
Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy and safety outcomes vs everolimus across prespecified subgroups.
No results found.